Xeris Biopharma Holdings (XERS) Non Operating Interest Expenses (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Non Operating Interest Expenses for 7 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 6.12% year-over-year to $6.9 million; the trailing twelve-month figure through Jun 2026 stood at $28.3 million (down 6.25% YoY), and the FY2025 full-year result was $29.1 million, down 4.59% from the prior year.
• Non Operating Interest Expenses advanced to $6.9 million in Q2 2026 per XERS's latest filing, from $6.9 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $8.0 million in Q2 2024 and bottomed at $3.4 million in Q2 2022.
• Historically, Non Operating Interest Expenses has averaged $6.4 million across 5 years, with a median of $7.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Non Operating Interest Expenses soared 142.61% in 2022, then slipped 7.5% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $4.4 million in 2022, then surged by 60.5% to $7.0 million in 2023, then increased by 9.86% to $7.7 million in 2024, then retreated by 6.9% to $7.2 million in 2025, then fell by 3.1% to $6.9 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $6.9 million, $6.9 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.